



Contacts:

Chris Martin

Vice President, Public Relations

CMartin@DavidJamesGroup.com | 630-670-2745

Becky Bunn, MSc

IASLC Project Specialist

Becky.Bunn@IASLC.org | 720-254-9509

Results From 3AURA Trial Show Osimertinib Reduces Risk of Disease Progression by 70 Percent in Patients With Non-Small Cell Lung Cancer

Vienna, Austria—December 6, 2016—Patients with non-small cell lung cancer on osimertinib experienced a higher rate of progression-free disease than patients enrolled in a control group that received only chemotherapy, according to research presented at the **IASLC 17th World Conference on Lung Cancer** in Vienna, Austria.

Osimertinib is a potent, irreversible, central nervous system active, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for sensitizing (EGFRm) and T790M resistance mutations.

In AURA 3, Dr. Vassiliki Papadimitrakopoulou, MD, Anderson Cancer Center in Houston, and colleagues randomized 419 patients with either osimertinib or platinum-pemetrexed plus either cisplatin 7or carboplatin.

Patients randomized in the osimertinib arm experienced improved progression-free survival rates compared with patients in pemetrexed arm. The median duration of response was 9.7 months with osimertinib and 4.1 months with pemetrexed. Patients in the osimertinib cohort suffered fewer adverse reactions (six percent versus 34 percent) than those in the pemetrexed group.

“Patients receiving osimertinib experienced a 70 percent reduction in the risk of disease progression without severe toxicity, and similar efficacy was seen in patients with CNS metastases at baseline” said to Dr. Papadimitrakopoulou. “These results show that osimertinib demonstrated a superior clinically-meaningful efficacy over platinum-pemetrexed, establishing the new standard of care for these patients.”

About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 6,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. Organized under the theme of “Together Against Lung Cancer,” the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit <http://wclc2016.iaslc.org/>.

About the IASLC:



www.iaslc.org

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit www.iaslc.org for more information.

###

